Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

SLNVery BullishM&Anews

High materiality9/10

Merck KGaA to acquire Silence Therapeutics for $1.3B equity value

Oct 19, 2026, 1:12 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Direct cash offer at a premium creates immediate upside for SLN; historical analogs show rapid pre-close moves followed by limited post-close volatility after deal certainty increases. However, deal risk remains if regulatory or shareholder hurdles arise.

AI summary

What happened, with direct paths to the underlying reporting

Silence Therapeutics will be acquired by Merck KGaA for $20 per ADS, valuing equity at about $1.3B and EV near $1.1B. The cash deal immediately lifts SLN’s stock by roughly 126% to $19.60, signaling strong deal certainty. Near-term moves depend on closing timing and regulatory approvals, with potential arbitrage dynamics for investors.

Merck KGaA to acquire Silence Therapeutics for $20 per ADS.
EV about $1.1B; equity around $1.3B.
SLN rose 125.7% to $19.60 on the news.
Deal news could lift related biotech names alongside SLN.
Closing timing and regulatory approvals to follow standard process.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.